Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02516332 · ClinicalTrials.gov registry record · NA

Exercise and Pharmacotherapy for Anxiety in Cardiac Patients

A NA study of Anxiety and Cardiovascular Disease, sponsored by Duke University.

Completed
Registry status
NA
Development phase
128
Enrollment target
1
Study location

NCT02516332: Completed NA study of Anxiety and Cardiovascular Disease, sponsored by Duke University.

NCT02516332 is a NA study of Anxiety and Cardiovascular Disease that has completed, run by Duke University. The registered enrollment target is 128 participants, below the 440-participant average among 364 other Anxiety trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02516332, a NA study of Anxiety and Cardiovascular Disease, has completed, sponsored by Duke University.

COMPLETED
Registry status
NA
Development phase
128 participants
Enrollment target
1
Study location

Study Summary

Coronary heart disease (CHD) is the leading cause of death in the United States; more than 600,000 Americans suffer a fatal cardiac event each year. Traditional CHD risk factors such as high blood pressure, smoking, and elevated cholesterol do not fully account for the timing and occurrence of CHD events and individuals with elevated levels of anxiety appear to have a greater risk of cardiovascular events. The present study will examine the impact of aerobic exercise and Lexapro in the treatment of anxiety and cardiovascular biomarkers among individuals with CHD.

Primary Outcome

The Hospital Anxiety and Depression Scale, Anxiety, is a 7-item subscale with scores ranging from 0-21, with higher scores indicating more anxiety.

Interventions

  • DRUG Placebo
  • DRUG Lexapro
  • BEHAVIORAL Supervised Aerobic Exercise

Study Locations (1)

North Carolina

  • Duke University Medical Center - Durham

Trial Details

FieldValue
Enrollment Target 128 participants
Start Date 2015-12
Est. Completion 2021-05
Phase NA
Duke University

1,725 total trials

What the finished NCT02516332 record still lists

NCT02516332 is an interventional study that assigns participants to a tested intervention. The registered 128 participants enrollment target is mid-sized for trials with a published cap, below the 440-participant average among 364 other Anxiety trials with a reported enrollment target (71% lower).

The record links to 2 conditions, with Anxiety appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT02516332 reports a single indexed study location in North Carolina.

Frequently Asked Questions

What is clinical trial NCT02516332 about?

NCT02516332 is a clinical study titled "Exercise and Pharmacotherapy for Anxiety in Cardiac Patients". Coronary heart disease (CHD) is the leading cause of death in the United States; more than 600,000 Americans suffer a fatal cardiac event each year. Traditional CHD risk factors such as high blood pressure, smoking, and elevated cholesterol do not fully account for the timing and occurrence of CHD e...

What is the current status of trial NCT02516332?

This trial is currently completed. It is a NA study. The enrollment target is 128 participants. The study started on 2015-12. Estimated completion is 2021-05.

What conditions does trial NCT02516332 study?

This clinical trial studies the following conditions: Anxiety, Cardiovascular Disease.

What interventions are being tested in trial NCT02516332?

The interventions under investigation include: Placebo (DRUG), Lexapro (DRUG), Supervised Aerobic Exercise (BEHAVIORAL).

Who is sponsoring clinical trial NCT02516332?

This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02516332 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Anxiety

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02516332's enrollment target sits among peer trials

128 136th of 364 higher than 229 of 364 other Anxiety trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Anxiety trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02870738 · 128 participants · Phase 2

    Bladder Directed vs. Pelvic Floor Therapy in IC/BPS

  • NCT03294460 · 128 participants · Phase 1

    Nicotinic Receptor Genetic Variation and Alcohol Reward

  • NCT04149977 · 128 participants · NA

    Blood Flow Restriction Therapy in Lower Limb Extensor Injuries

  • NCT04373057 · 128 participants · Phase 1

    Prebiotic Galacto-oligosaccharide and Acute GVHD

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02516332, the US trial registry maintained by the National Library of Medicine. NCT02516332 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.